| |
|
| | ||
|
| | |||||
| | |||||
| | | |
More than 2,500 employees in North America, Europe and Australia contribute to the Gilead mission of advancing patient care by developing ground-breaking therapeutics to treat life-threatening infectious diseases. Gilead Sciences is committed to increasing global access to Truvada and Viread for people living with HIV. The Gilead Access Program helps address this need in the developing world. www.gileadaccess.orgwww.gileadaccess.org. --> | |
|
| | | |
| |
||
| |
Gilead Sciences Completes Acquisition of Myogen | |
| |
||
| |
Gilead Sciences to Present at the Credit Suisse Healthcare Conference on Friday, November 17th | |
| |
||
| |
Gilead Sciences Successfully Completes Tender Offer for Shares of Myogen With Over 91.3 Percent of Shares Tendered | |
| |
November 28 - 29, 2006 3rd Annual Lazard Capital Markets Life Sciences Conference New York, NY November 29 - December 1, 2006 18th Annual Piper Jaffray Healthcare Conference New York, NY December 5 - 7, 2006 NASDAQ 18th Investor Program London, United Kingdom |
| |
|||
| |
|||
| |
|
|
Download Full Prescribing Information (PDF) Visit www.atripla.com |
| |
|||
| |
|
|
Download Full Prescribing Information (PDF)
Visit www.truvada.com |
| |
|||
| |
|
|
Download Full Prescribing Information (PDF)
Visit www.hepsera.com |
| |
|||
| Home | |
Search | |
Site Index | |
Contact | |
| |
©2006 Gilead | |
Disclaimer PRIVACY POLICY |